Vertex Pharmaceuticals Company Insiders

VRTX Stock  USD 418.01  0.69  0.17%   
Vertex Pharmaceuticals' insiders are aggressively selling. The analysis of the overall insider sentiment regarding Vertex Pharmaceuticals suggests that vertually all insiders are panicking. Vertex Pharmaceuticals employs about 5.4 K people. The company is managed by 37 executives with a total tenure of roughly 216 years, averaging almost 5.0 years of service per executive, having 145.95 employees per reported executive.
Joshua Boger  Chairman
Executive Director and Chairman of Science and Technology Committee
Jeffrey Leiden  Chairman
Chairman of the Board and Presidentident, CEO

Vertex Pharmaceuticals' Insider Buying Vs Selling

0

 
Selling
 
Buying

Latest Trades

2024-02-26Ourania TatsisDisposed 354 @ 425.7View
2024-02-20Ourania TatsisDisposed 480 @ 420.79View
2024-02-12Amit SachdevDisposed 3222 @ 420.24View
2024-01-08Jeffrey M LeidenDisposed 6648 @ 419.07View
2023-11-06Bruce I SachsDisposed 11250 @ 385View
2023-10-31Carmen BozicDisposed 5651 @ 355.92View
2023-10-24Greg StantonDisposed @ 369.38
2023-10-17Carmen BozicDisposed 5651 @ 373.25View
2023-10-16Jeffrey M LeidenDisposed 12962 @ 374View
2023-10-06Sangeeta N BhatiaDisposed 242 @ 360View
2023-10-03Carmen BozicDisposed 5651 @ 345.28View
2023-10-02Jonathan BillerDisposed 610 @ 346.76View
2023-09-19Carmen BozicDisposed 5651 @ 351View
2023-08-23Ourania TatsisDisposed 2500 @ 355View
2023-08-09Sangeeta N BhatiaDisposed 242 @ 345.51View
Monitoring Vertex Pharmaceuticals' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vertex Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.
For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.

Vertex Pharmaceuticals' Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Vertex Pharmaceuticals' future performance. Based on our forecasts, it is anticipated that Vertex will maintain a workforce of slightly above 5400 employees by April 2024.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid

Vertex Pharmaceuticals' latest congressional trading

Congressional trading in companies like Vertex Pharmaceuticals, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Vertex Pharmaceuticals by those in governmental positions are based on the same information available to the general public.
2023-10-24Representative Greg StantonDisposed Under $15KVerify
2022-10-06Senator Tommy TubervilleAcquired Under $15KVerify
2022-03-29Representative William R. KeatingAcquired Under $15KVerify
2021-01-28Representative Peter MeijerDisposed Under $15KVerify
2020-12-18Representative Dean PhillipsAcquired Under $15KVerify
2020-11-19Representative Kenny MarchantDisposed Under $15KVerify
2019-06-24Representative Donna ShalalaDisposed Under $15KVerify
2019-02-04Senator Jack ReedAcquired Under $15KVerify

Vertex Pharmaceuticals Management Team Effectiveness

The company has return on total asset (ROA) of 0.1317 % which means that it generated a profit of $0.1317 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2299 %, meaning that it created $0.2299 on every $100 dollars invested by stockholders. Vertex Pharmaceuticals' management efficiency ratios could be used to measure how well Vertex Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to rise to 0.21 in 2024. Return On Assets is likely to rise to 0.17 in 2024. At this time, Vertex Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 9 B in 2024, whereas Intangible Assets are likely to drop slightly above 424.7 M in 2024.
Net Income Applicable To Common Shares is likely to rise to about 4 B in 2024, whereas Common Stock Shares Outstanding is likely to drop slightly above 153.1 M in 2024.

Vertex Pharmaceuticals Workforce Comparison

Vertex Pharmaceuticals is rated first in number of employees category among related companies. The total workforce of Health Care industry is at this time estimated at about 57,628. Vertex Pharmaceuticals holds roughly 5,400 in number of employees claiming about 9% of equities under Health Care industry.

Vertex Pharmaceuticals Profit Margins

The company has Profit Margin (PM) of 0.37 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.38 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.38.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin1.090.8717
Significantly Up
Slightly volatile

Vertex Pharmaceuticals Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Vertex Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Vertex Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Vertex Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2024-03-01
0.4853
33
68
 259,613 
 210,886 
2023-12-01
0.3636
8
22
 39,464 
 137,239 
2023-09-01
0.25
4
16
 21,465 
 80,624 
2023-06-01
0.3571
15
42
 52,495 
 95,459 
2023-03-01
0.2611
41
157
 384,973 
 272,222 
2022-12-01
0.25
5
20
 14,401 
 6,140 
2022-09-01
0.2326
10
43
 14,431 
 179,452 
2022-06-01
0.2577
25
97
 50,564 
 92,544 
2022-03-01
0.4146
34
82
 357,595 
 172,217 
2021-12-01
0.2857
2
7
 391.33 
 854.00 
2021-09-01
5.0
5
1
 25,360 
 766.00 
2021-06-01
0.4333
13
30
 38,656 
 15,097 
2021-03-01
0.3043
35
115
 361,380 
 221,413 
2020-12-01
0.2581
8
31
 27,921 
 30,580 
2020-09-01
0.2464
17
69
 20,513 
 45,069 
2020-06-01
0.1866
53
284
 438,679 
 885,271 
2020-03-01
0.1884
62
329
 461,392 
 654,153 
2019-12-01
0.4151
44
106
 502,786 
 899,090 
2019-09-01
1.1765
20
17
 72,210 
 34,914 
2019-06-01
0.6939
34
49
 334,291 
 418,016 
2019-03-01
0.6667
54
81
 621,960 
 384,841 
2018-12-01
1.0
35
35
 203,967 
 72,150 
2018-09-01
0.4583
22
48
 78,828 
 157,158 
2018-06-01
0.6875
44
64
 324,559 
 629,675 
2018-03-01
0.4507
64
142
 742,260 
 740,309 
2017-12-01
0.1772
14
79
 38,532 
 454,232 
2017-09-01
0.4128
45
109
 614,825 
 1,222,983 
2017-06-01
0.9038
47
52
 643,090 
 1,162,398 
2017-03-01
1.0
31
31
 606,480 
 280,815 
2016-12-01
0.2667
16
60
 90,078 
 181,657 
2016-09-01
0.2581
16
62
 131,351 
 210,780 
2016-06-01
0.5172
30
58
 147,291 
 175,301 
2016-03-01
0.3168
32
101
 801,066 
 424,286 
2015-12-01
0.1931
28
145
 258,960 
 672,678 
2015-09-01
0.3158
36
114
 512,208 
 402,209 
2015-06-01
0.4198
55
131
 527,101 
 640,249 
2015-03-01
0.4155
59
142
 920,430 
 496,097 
2014-12-01
0.3518
70
199
 730,561 
 724,322 
2014-09-01
0.5
62
124
 1,012,921 
 1,367,744 
2014-06-01
0.6471
22
34
 312,484 
 263,026 
2014-03-01
0.8519
23
27
 884,338 
 200,208 
2013-12-01
0.3067
23
75
 45,029 
 156,760 
2013-09-01
0.4103
48
117
 683,408 
 754,870 
2013-06-01
0.5169
46
89
 1,059,116 
 1,990,346 
2013-03-01
5.25
21
4
 813,910 
 139,247 
2012-12-01
0.4167
20
48
 117,492 
 255,389 
2012-09-01
0.6364
35
55
 596,510 
 257,686 
2012-06-01
0.587
54
92
 946,136 
 1,360,188 
2012-03-01
1.2222
22
18
 854,638 
 286,681 
2011-12-01
0.4063
13
32
 682,503 
 91,099 
2011-09-01
0.5286
37
70
 520,397 
 310,496 
2011-06-01
0.44
33
75
 380,824 
 383,766 
2011-03-01
0.7879
26
33
 858,190 
 358,570 
2010-12-01
0.2143
3
14
 4,727 
 43,831 
2010-09-01
1.3333
16
12
 393,050 
 42,407 
2010-06-01
0.8667
13
15
 187,400 
 66,289 
2010-03-01
1.2667
19
15
 933,209 
 113,053 
2009-12-01
0.6296
17
27
 1,222,774 
 133,642 
2009-09-01
0.6444
29
45
 400,492 
 270,547 
2009-06-01
0.5652
26
46
 320,801 
 432,731 
2009-03-01
1.5
30
20
 1,602,276 
 157,292 
2008-12-01
0.24
12
50
 114,453 
 250,356 
2008-09-01
0.6667
32
48
 604,764 
 479,053 
2008-06-01
0.1351
20
148
 353,281 
 111,281 
2008-03-01
23.5
47
2
 840,804 
 12,735 
2007-12-01
0.1509
24
159
 198,301 
 388,010 
2007-09-01
1.0
31
31
 689,645 
 247,790 
2007-06-01
0.766
36
47
 340,699 
 213,417 
2007-03-01
0.8689
53
61
 755,210 
 135,073 
2006-12-01
0.4894
46
94
 221,211 
 388,642 
2006-09-01
0.84
21
25
 505,320 
 360,640 
2006-06-01
0.8387
26
31
 318,655 
 275,709 
2006-03-01
0.9302
40
43
 1,302,176 
 206,755 
2005-12-01
0.3784
14
37
 129,200 
 318,425 
2005-09-01
0.7407
20
27
 194,921 
 237,100 
2005-06-01
1.0714
15
14
 132,500 
 115,875 
2005-03-01
1.625
26
16
 337,778 
 112,000 
2004-12-01
0.8519
23
27
 273,442 
 156,871 
2004-09-01
0.3143
11
35
 71,509 
 241,309 
2004-06-01
0.7544
43
57
 814,500 
 375,813 
2004-03-01
0.6923
27
39
 172,636 
 222,891 
2003-12-01
1.3704
37
27
 507,446 
 532,309 
2003-09-01
0.4333
13
30
 194,891 
 404,982 
2003-06-01
0.8571
6
7
 45,000 
 82,568 

Vertex Pharmaceuticals Notable Stakeholders

A Vertex Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Vertex Pharmaceuticals often face trade-offs trying to please all of them. Vertex Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Vertex Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
MD FASNPresident CEOProfile
Joshua BogerExecutive Director and Chairman of Science and Technology CommitteeProfile
Jeffrey MDExecutive ChairmanProfile
Jeffrey LeidenChairman of the Board and Presidentident, CEOProfile
Reshma KewalramaniExecutive Vice President - Global Medicines Development and Medical Affairs and Chief Medical OfficerProfile
Michael PariniExecutive Vice President and Chief Legal OfficerProfile
John GraySenior Vice President Genetic TherapiesProfile
Ian SmithCFO, Executive Vice PresidentProfile
Paul SilvaSenior Vice President Corporate ControllerProfile
Jeffrey ChodakewitzChief Medical Officer and Senior Vice President - Global Medicines DevelopmentProfile
Amit SachdevSenior Vice President - Global Government Strategy, Market Access and ValueProfile
Charles WagnerCFO, Executive Vice PresidentProfile
Michael PartridgeVice President - Investor RelationsProfile
Kimberly WhiteSenior Vice President and Chief Communications OfficerProfile
Thomas GraneyCFO, Senior Vice PresidentProfile
Charles MilsteinExecutive Vice President Chief Legal and Administrative OfficerProfile
Stuart BScExecutive COOProfile
Stuart ArbuckleChief Commercial Officer and Executive VPProfile
William YoungIndependent DirectorProfile
Alan GarberIndependent DirectorProfile
Margaret McGlynnIndependent DirectorProfile
Sangeeta BhatiaDirectorProfile
Terrence KearneyIndependent DirectorProfile
David AltshulerIndependent DirectorProfile
Elaine UllianCo-Lead Independent DirectorProfile
David GreenwayDirectorProfile
Bruce SachsCo-Lead Independent DirectorProfile
Lloyd CarneyIndependent DirectorProfile
Yuchun LeeIndependent DirectorProfile
Jonathan JDExecutive OfficerProfile
Stephanie FranklinSenior OfficerProfile
Mike TirozziSVP OfficerProfile
Damian EsqChief VPProfile
Nina DevlinSenior OfficerProfile
Kristen AmbroseTax, AccountingProfile
Ourania TatsisEx OfficerProfile
Susie LisaSenior RelationsProfile

About Vertex Pharmaceuticals Management Performance

The success or failure of an entity such as Vertex Pharmaceuticals often depends on how effective the management is. Vertex Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Vertex management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Vertex management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for 2024
Return On Capital Employed 0.20  0.21 
Return On Assets 0.16  0.17 
Return On Equity 0.21  0.22 
The data published in Vertex Pharmaceuticals' official financial statements usually reflect Vertex Pharmaceuticals' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Vertex Pharmaceuticals. For example, before you start analyzing numbers published by Vertex accountants, it's critical to develop an understanding of what Vertex Pharmaceuticals' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Vertex Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Vertex Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Vertex Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Vertex Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Vertex Pharmaceuticals' management manipulating its earnings.

Vertex Pharmaceuticals Workforce Analysis

Traditionally, organizations such as Vertex Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Vertex Pharmaceuticals within its industry.

Vertex Pharmaceuticals Manpower Efficiency

Return on Vertex Pharmaceuticals Manpower

Revenue Per Employee1.8M
Revenue Per Executive265.9M
Net Income Per Employee670.3K
Net Income Per Executive97.8M
Working Capital Per Employee2M
Working Capital Per Executive286.4M
When determining whether Vertex Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Vertex Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Vertex Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Vertex Pharmaceuticals Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vertex Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.
For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.
You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.

Complementary Tools for Vertex Stock analysis

When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Is Vertex Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vertex Pharmaceuticals. If investors know Vertex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vertex Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.181
Earnings Share
13.9
Revenue Per Share
38.297
Quarterly Revenue Growth
0.093
Return On Assets
0.1317
The market value of Vertex Pharmaceuticals is measured differently than its book value, which is the value of Vertex that is recorded on the company's balance sheet. Investors also form their own opinion of Vertex Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Vertex Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vertex Pharmaceuticals' market value can be influenced by many factors that don't directly affect Vertex Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vertex Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vertex Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vertex Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.